CoChat

The therapeutic human CD38 antibody daratumumab improves the anti-myeloma effect of newly emerging multi-drug therapies

Open access
van der Veer, M S, de Weers, M, van Kessel, B, Bakker, J M, Wittebol, S, Parren, P W H I, Lokhorst, H M, Mutis, T · 2011 · Blood Cancer Journal
Cited by 100

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

Abstract

Multiple myeloma (MM) is an incurable malignancy of antibody-producing clonal plasma cells. The mean life expectancy of patients has remained at <3 years during the past few decades. The introduction of a new generation drug regimens including an immunomodulatory agent such as lenalidomide (LEN) or a proteasome inhibitor such as bortezomib (BORT) used alone or in combination with classical anti-MM drugs melphalan (MEL), dexamethasone (DEX) or prednisone (PRED) has significantly improved the overall survival of MM patients. 1 , 2 All treatment strategies, including multidrug regimens, however, are eventually hampered by the development of drug resistance. 3 Targeted immunotherapy, based on human antibodies against relevant tumor antigens has shown to be a feasible and highly promising approach in hematological malignancies that can be effectively combined with chemotherapy to further increase the potency of anti-tumor effects. For instance in several B-cell malignancies, clinically approved human antibodies against CD20 are now being successfully combined with fludarabine, cyclophosphamide or LEN. 4 , 5 Building on this knowledge and to achieve a similar goal in the MM setting, we recently generated daratumumab (DARA), a human CD38 antibody with broad-spectrum killing activity. 6 We have shown that DARA mediates strong lysis of MM cells via CDC (complement-dependent cytotoxicity) as well as ADCC (antibody-dependent cellular cytotoxicity), although the potency of autologous ADCC was donor-dependent. In our initial work to combine DARA with novel chemotherapeutics, we have demonstrated that DARA-mediated cellular lysis of MM cells is significantly improved by LEN, mainly because of the potent capacity of LEN to activate the effector cells of ADCC. 7 Current clinical practice, however, shows that the future of successful MM treatment lies in the use of drug combination regimens. It appears essential to identify regimens in which individual components synergize to obtain the greatest achievable effects. Therefore, we now explored the potential clinical benefit of combining targeted DARA therapy with newly emerging multi-drug chemotherapy regimens. To this end, we used a recently developed ex vivo flow cytometry-based assay platform, 7 which enables us to enumerate and subsequently deduce the drug/antibody-mediated lysis of primary CD138 + MM cells directly in bone marrow samples from the MM patients. The assays are performed with bone marrow mononuclear cells (BM-MNC), thus without the need for separating malignant cells from autologous effector cells and tumor-supporting accessory cells, such as stromal cells. With this ex vivo assay system, we first addressed the benefits of combining DARA with both LEN and BORT, since not only LEN but also BORT may enhance the therapeutic efficacy of DARA by sensitizing tumor cells for antibody-mediated lysis. In a series of experiments, we incubated BM-MNC from 16 MM patients, containing 2–20% malignant plasma cells, either with medium alone or with combinations of LEN, BORT and DARA at carefully selected individual concentrations inducing half-maximal lysis of MM cells. An antibody against an irrelevant antigen (Keyhole Limpet Hemocyanin (KLH)) was used as an isotype control. After 48 h, we harvested the cells, labeled them with a monoclonal CD138 antibody and enumerated the surviving CD138 + MM cells using single-platform flow cytometry, to assess the percentage of MM cell lysis in each sample ( Figure 1a ) relative to that obtained with the control antibody KLH, which induced negligible MM cell lysis (data not shown). LEN and BORT alone or in combination caused low to moderate lysis of MM cells (mean lysis 10%, 18% and 25%, respectively). Addition of DARA significantly increased the MM cell lysis by more than twofold in all combinations ( P =0.001). The highest MM cell lysis was observed with the triple LEN-BORT-DARA combination. Notably, combination with DARA seemed to improve MM cell lysis especially in the samples that poorly responded to LEN and BORT (MM cell lysis <30%; Figure 1a ). To evaluate this, we analyzed the data of LEN/BORT high and low responders separately ( Figures 1b and c ). A significant improvement of MM cell lysis by DARA was observed in the LEN/BORT low-responder subset particularly ( Figure 1c ) and the effect was synergistic. This group included cells from five patients who had been treated in the clinic with LEN and/or BORT without success ( Figure 1d ). Figure 1 Addition of DARA to BORT-LEN significantly increases the MM cell lysis in BM-MNC of MM patients, particularly in LEN/BORT low responder or refractory patients. ( a ) BM-MNC from MM patients ( n =16), containing 2–20% CD138 + MM cells as detected by flow cytometry were incubated with LEN (3 μ M ), BORT (3 n M ) and DARA (10 μg/ml) alone or in combination for 48 h in RPMI+ 10% fetal bovine serum in 96-well u bottom plates in fully humidified incubators at 37 °C, 5% CO 2 -air mixture. Survi

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/bcj.2011.42

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Cited by

See all 100

Metadata

Authors
van der Veer, M. S., de Weers, M., van Kessel, B., Bakker, J. M., Wittebol, S., Parren, P. W. H. I., Lokhorst, H. M., & Mutis, T.
Venue
Blood Cancer Journal
Published
2011-10-28
Volume
1
Issue
10
Pages
e41-e41
ISSN
2044-5385 (ISSN-L)
OpenAlex
W1967198288
Cited by
100
References
1
FWCI
2.83
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.